Provided herein are methods of treating one or more symptoms associated with neuroendocrine tumors, such as diarrhea and flushing episodes associated with carcinoid tumors and methods of treating carcinoid syndrome, comprising orally administering compositions comprising octreotide or a pharmaceutically acceptable salt thereof.
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Provided herein are methods of treating one or more symptoms associated with neuroendocrine tumors, such as diarrhea and flushing episodes associated with carcinoid tumors and methods of treating carcinoid syndrome, comprising orally administering compositions comprising octreotide or a pharmaceutically acceptable salt thereof.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Provided herein are methods of treating one or more symptoms associated with neuroendocrine tumors, such as diarrhea and flushing episodes associated with carcinoid tumors and methods of treating carcinoid syndrome, comprising orally administering compositions comprising octreotide or a pharmaceutically acceptable salt thereof.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates generally to encapsulated pharmaceutical compositions enabling improved oral delivery and methods of using such compositions.
A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/52 - Sustained or differential release type
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates generally to encapsulated pharmaceutical compositions enabling improved oral delivery and methods of using such compositions.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/78 - Polymers containing oxygen of acrylic acid or derivatives thereof
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations with enhanced intestinal absorbance; carriers for pharmaceutical and veterinary preparations, namely drug delivery agents; mediums for pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations for oral delivery.
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Methods are disclosed of treating or preventing hypotension (e.g., neurogenic orthostatic hypotension or postprandial hypotension) or portal hypertension (e.g., bleeding esophageal varices associated with portal hypertension) or ascites (e.g., ascites associated with liver cirrhosis), by oral administration to affected subjects of compositions comprising a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
27.
Oral octreotide administered in combination with other therapeutic agents
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 38/27 - Growth hormone [GH], i.e. somatotropin
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations with enhanced intestinal absorbance; carriers for pharmaceutical and veterinary preparations; mediums for pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations for oral delivery. Contract and custom manufacturing of pharmaceutical and veterinary preparations. Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; provision of information and consultancy in relation to the aforesaid services.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations with enhanced intestinal absorbance; carriers for pharmaceutical and veterinary preparations; mediums for pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations for oral delivery. Contract and custom manufacturing of pharmaceutical and veterinary preparations. Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; provision of information and consultancy in relation to the aforesaid services.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Health and medical education services. Medical services; medical treatment services; medical care; health and medical counselling; providing health and medical information. Providing personal and emotional support for patients with acromegaly and their families.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations with enhanced intestinal absorbance; carriers for pharmaceutical and veterinary preparations; mediums for pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations for oral delivery. Medical and surgical apparatus, instruments and devices; apparatus, instruments and devices for storing and dispensing medical and surgical preparations; instruments and apparatus for the administration of therapy and prophylaxis preparations and substances. Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; provision of information and consultancy in relation to the aforesaid services.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical and veterinary preparations for the treatment and prophylaxis of infections, physiological disorders, hormonal disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genito-urinary disorders, musculoskeletal disorders, and blood disorders.
(2) Pharmaceutical preparations for the treatment and prophylaxis of physiological disorders, hormonal disorders and cell proliferation. (1) Pharmaceutical research and development services; pharmaceutical testing and clinical trials; provision of information regarding pharmaceutical research and development, pharmaceutical testing and clinical trials in connection with the treatment and prophylaxis of infections, physiological disorders, hormonal disorders, respiratory diseases, gastrointestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genito-urinary disorders, musculoskeletal disorders, and blood disorders.
(2) Pharmaceutical research and development services; pharmaceutical testing and clinical trials; provision of information regarding pharmaceutical research and development, pharmaceutical testing and clinical trials in connection with the treatment and prophylaxis of physiological disorders, hormonal disorders and cell proliferation.
38.
Pharmaceutical compositions and related methods of delivery
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary preparations for the treatment and prophylaxis of infections, physiological disorders, hormonal disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genito-urinary disorders, musculoskeletal disorders, and blood disorders. Contract and custom manufacturing of pharmaceutical and veterinary preparations. Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; provision of information and consultancy in relation to the aforesaid services; all the abovementioned services being in connection with the treatment and the prophylaxis of infections, physiological disorders, hormonal disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genito-urinary disorders, musculoskeletal disorders, and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations with enhanced intestinal absorbance; carriers for pharmaceutical and veterinary preparations; mediums for pharmaceutical and veterinary preparations; pharmaceutical and veterinary preparations for oral delivery. Medical and surgical apparatus, instruments and devices; apparatus, instruments and devices for storing and dispensing medical and surgical preparations; instruments and apparatus for the administration of therapy and prophylaxis preparations and substances. Scientific and technological services and research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; provision of information and consultancy in relation to the aforesaid services.
46.
Pharmaceutical compositions and related methods of delivery
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; veterinary preparations; preparations and formulations containing octreotide for pharmaceutical and veterinary use; octreotide compounds and formulations for pharmaceutical and veterinary purposes.
49.
Compositions capable of facilitating penetration across a biological barrier
This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.
